 | ||||||||||||||||
 |
|
 Introducing a new line of products from NuGEN®... The Applause™ Systems, practical solutions for today's RNA amplification challenges Customer Feature Publication of the Month NuGEN Names Dr. Lutz Kirchrath Managing Director of European Field Operations Conducting Biomarker Research? Hear Dr. Jo Vandesompele's Successful Strategy for Prognostic Multigene Expression Classification of Cancer Patients. Have you been published recently? Send us a link and a brief overview of your papers and posters enabled by a NuGEN Ovation® System. We'll include them in our database of scientific publications and consider your submission for an upcoming issue of our monthly newsletter. |
|
|
Introducing a new line of products from NuGEN®... The Applause™ Systems, practical solutions for today's RNA amplification challenges  The Applause™ Systems offer NuGEN's proven SPIA® technology for total RNA sample sizes starting at 50 ng. Powerful and cost effective, Applause™ delivers a single-tube, single-purification, single-day assay as a more practical solution to meet everyday microarray and qPCR amplification needs. The new line of Applause™ products are NuGEN's latest solutions for genomic sample preparation. The first members of the Applause family, the WT-Amp ST and WT-Amp Plus ST systems provide the perfect workflow to produce targets appropriate for Affymetrix GeneChip® Gene ST and Exon ST array analysis.
Customer Feature Phenotype Analysis of Endometrial Macrophages from Limited RNA Samples on Agilent Expression Arrays
One of the characteristics of pregnancy is that there is a large-scale infiltration of macrophages into the uterine endoemtrium. The function of these cells is unknown and it has been difficult to purify sufficient quantities to characterize their functional properties. Dr. Hansen used the cow as a model to determine the phenotype of endometrial macrophages. This is a good model system because sufficient quantity of tissue is obtained to allow purification of endometrial macrophages via flow cytometry. Using CD14 as a marker, the macrophages were purified from the endometrium of pregnant cows and the gene expression profile compared to that of CD14+ cells in the blood. The number of cells obtained from the endometrium is low (maximum of 100,000) and the NuGEN amplification technology has proven crucial in amplification of RNA to produce high quality material for microarray analysis using the Agilent system. The preliminary analyses indicate a significant change in gene expression as CD14+ monocytes leave the blood and become resident in the endometrium as CD14+ macrophages. These results suggest an alteration in the macrophage phenotype, therefore, a new functional role in the endometrium during pregnancy. This study with Dr. Peter Hansen at the University of Florida and MOgene highlights the need for the NuGEN technology where small amounts of RNA from Bovine embryo were amplified. This was made possible by using the NuGEN WT-Ovation Pico RNA Amplification system and Agilent arrays to obtain global gene expression data which otherwise would not have been possible. Publication of the Month
(1) Institute of Pathology, University Hospital, Albert-Ludwigs University, Breisacherstr. 115a, 79106 Freiburg, Germany (2) Center for Biosystems Analysis (ZBSA), Freiburg Center for Data Analysis and Modeling (FDM), Albert-Ludwigs University, Freiburg, Germany (3) Department of Surgery, University Hospital, Albert-Ludwigs University, Freiburg, Germany Received: 3 June 2008 Revised: 4 November 2008 Accepted: 6 November 2008 Published online: 6 December 2008 Summary Formalin-Fixed, Paraffin Embedded (FFPE) tissue biopsies and surgical resections are among the most precious and most challenging samples for molecular microarray analysis. The clinical information associated with these samples represents a rich source of phenotypic information that can be correlated with the expression data. However, the RNA extracted from these samples is usually of extremely poor quality and severely impacts the generation of biologically relevant expression data. The authors of this study used matched fresh-frozen and FFPE resection specimens representing tumors and normal adjacent tissue from patients undergoing colorectal cancer surgery. Tumor cells were microdissected from both frozen and FFPE stained sections resulting in >80% tumor cell purity in the samples. RNA from a colorectal cancer cell line and Stratagene Universal Human Reference RNA were used as controls. RNA was isolated and 100 ng was amplified using the WT-Ovation FFPE RNA Amplification System. Following fragmentation and labeling, 5 ug of amplified cDNA from each sample was hybridized to GeneChip® HG-U133_Plus_2 arrays from Affymetrix and the resulting data analyzed using standard assessment criteria from the "simpleaffy" R package as well as supervised and unsupervised clustering methods. Excellent data was derived from all samples enabling the elimination of the measurement differences between FFPE and Frozen samples. This allowed for the detection of tumor specific expression profiles of 10 transcripts including TOPOIIa, TYMS, and STK6 which were subsequently validated using QPCR in both frozen and FFPE samples. The authors conclude that this approach is a highly valuable tool to examine relevant biological gene expression profiles from archival tissue specimens in retrospective studies. NuGEN Names Dr. Lutz Kirchrath Managing Director of European Field Operations
Dr. Kirchrath was most recently European pharmaceutical district manager for Affymetrix where he developed targeted sales and business development strategies, and managed cross-functional workflows between sales, marketing, field support, customer service, and finance teams. Prior to Affymetrix, Dr. Kirchrath spent nearly five years in sales development and applications support positions with Amersham Pharmacia Biotech in Freiburg, Germany. "I am excited to join the company that has revolutionized nucleic acid sample preparation enabling life science researchers to mine precious samples on various genomic analysis platforms," Kirchrath stated. "In addition, I will be able to continue to drive the customer focus that NuGEN has made a priority and bring innovative solutions to scientists' toughest challenges in clinical research, expression profiling, and biomarker and signature discovery." Kirchrath earned his doctorate in microbiology and molecular genetics and his diploma in biology magna cum laude from the Institute for Microbiology at the Heinrich-Heine Universitat, Dusseldorf. He is a native of Dusseldorf, Germany. Conducting Biomarker Research? Hear Dr. Jo Vandesompele's Successful Strategy for Prognostic Multigene Expression Classification of Cancer Patients.
If this message has been forwarded to you, you may join our mailing list. NuGEN Technologies, Inc. 821 Industrial Road, Unit A San Carlos, CA 94070 Telephone: 888-654-6544 or 650-590-3600 www.nugeninc.com |
|
||||||||||
